Axsome Therapeutics, Inc. (AXSM)
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market.
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?
AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.
1 Under-the-Radar Biotech Stock to Buy and Hold
Axsome Therapeutics' revenue is growing rapidly. The company's pipeline should lead to many new approvals and label expansions.
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025.
Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity.
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Axsome Therapeutics reported Q2 2024 revenues of $87.2 million, with Auvelity sales growing 135% year-over-year. The company's SG&A and R&D expenses significantly increased, leading to wider net losses despite revenue growth. Auvelity faces stiff competition in the depression market, with uncertain positioning and high marketing expenses.
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
Why Axsome Therapeutics Stock Is Sinking Today
Axsome's Q2 revenue beat estimates, but the company posted a wider net loss than expected. The primary culprit behind the disappointing bottom line were noncash charges of $26 million.
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Conference Call Participants Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald Joon Lee - Truist Securities Raghuram Selvaraju - H.C. Wainwright Jason Gerberry - Bank of America Ami Fadia - Needham & Company Yatin Suneja - Guggenheim Partners David Amsellem - Piper Sandler Joel Beatty - Baird Joseph Thome - TD Cowen David Hoang - Citigroup Graig Suvannavejh - Mizuho Securities Ashwani Verma - UBS Myles Minter - William Blair Matt Kaplan - Ladenburg Thalmann Operator Hello, and welcome to the Axsome Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast.
Does Axsome (AXSM) Have the Potential to Rally 48.44% as Wall Street Analysts Expect?
The mean of analysts' price targets for Axsome (AXSM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1 per share a year ago.
